Evaxion A (EVAX) Other Non-Current Liabilities (2021 - 2025)
Evaxion A posted quarterly Other Non-Current Liabilities of $158000.0 for Q4 2025, up 12.06% year-on-year from $141000.0 in Q4 2024, and little changed on a QoQ basis from $158000.0 in Q2 2025.
Evaxion A (EVAX) has 5 years of Other Non-Current Liabilities data on file, last reported at $158000.0 in Q4 2025.
- For the quarter ending Q4 2025, Other Non-Current Liabilities rose 12.06% year-over-year to $158000.0; the trailing twelve-month figure through Dec 2025 stood at $158000.0 (up 12.06% YoY), and the FY2025 full-year result was $158000.0, up 12.06% from the prior year.
- Other Non-Current Liabilities for Q4 2025 stood at $158000.0, roughly flat from $158000.0 in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $573000.0 in Q4 2022 and bottomed at $52000.0 in Q1 2021.
- The 5-year median for Other Non-Current Liabilities is $149000.0 (2023), against an average of $167461.5.
- The widest annual swing landed in 2022, when Other Non-Current Liabilities soared 274.51%; it then plunged 74.0% in 2023.
- A 5-year view of Other Non-Current Liabilities shows it stood at $153000.0 in 2021, then jumped by 274.51% to $573000.0 in 2022, then slumped by 74.0% to $149000.0 in 2023, then decreased by 5.37% to $141000.0 in 2024, then increased by 12.06% to $158000.0 in 2025.
- The last three Other Non-Current Liabilities figures came in at $158000.0 (Q4 2025), $158000.0 (Q2 2025), and $141000.0 (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 158,000.00 |
| Jun 30, 2025 | 158,000.00 |
| Dec 31, 2024 | 141,000.00 |
| Jun 30, 2024 | 145,000.00 |
| Dec 31, 2023 | 149,000.00 |
| Jun 30, 2023 | 147,000.00 |
| Dec 31, 2022 | 573,000.00 |
| Jun 30, 2022 | 141,000.00 |
| Mar 31, 2022 | 150,000.00 |
| Dec 31, 2021 | 153,000.00 |
| Sep 30, 2021 | 157,000.00 |
| Jun 30, 2021 | 53,000.00 |
| Mar 31, 2021 | 52,000.00 |